Plasma biomarker analysis in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)

Authors
Publication date
1 May 2015
Publisher

Abstract

Experimentele farmacotherapi

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Leiden University Scholary Publications

    redirect
    oaioai:scholarlypublications.univ...
    Last time updated on 12/03/2021